Mountain Valley MD Holdings Inc. announced the recent peer-reviewed publication of the Company's SoluvecTM study data in the journal, Therapeutic Delivery. The published study highlights the benefits of the Company's patented SoluvecTM formulation, a novel, solvent-free aqueous Ivermectin invention. This proprietary SoluvecTM formulation was developed using the Company's patented QuicksolTM solubilization technology, which aims to address the poor solubility challenges associated with Ivermectin and potentially other macrocyclic lactones.

The study confirmed that parenteral administration of SoluvecTM led to an Ivermectin drug exposure approximately seven times higher than traditional oral drug dosing, with greater bioavailability, offering potential for enhanced therapeutic effectiveness. Key Findings from the Study: Improved Solubility with SoluvecTM: In the resolubilized product, SoluvecTM, Ivermectin was present as a mix of 28.0 nm particles and polysorbate-solubilized free Ivermectin. The total concentration was approximately 2,500 times greater than that of free Ivermectin in water.

IVM Exposure Seven Times Higher: In beagle dogs treated parenterally with Soluvec (subcutaneous or intramuscular dosing), total exposure of Ivermectin was seven-times higher than in dogs receiving a non-solubilized Ivermectin tablet of the same dose orally. Increased Duration of Exposure: Peak levels were higher and, most importantly for ease of treatment, duration of exposure was reliably greater with parenteral dosing; all Soluvec- treated animals had detectable IVM at 48 h, versus none of the non-solublized Ivermectin orally dosed animals. Lower Doses Possible: Enhanced bioavailability of IVM in SoluvecTM suggests that a lower dose may achieve the desired therapeutic effects, potentially leading to reduced treatment costs and fewer side effects.

Safety Profile: Research underscores favourable safety profile of SoluvecTM, with minimal side effects generally observed in test subjects. Potential Human and Livestock Applications: The results point to the possibility of easier treatment regimens and improved therapeutic outcomes not just for livestock but potentially for humans as well. On May 8, 2023, the Company announced it had entered into a licensing and manufacturing license agreement with a privately held Ontario corporation for its SoluvecTM1% animal husbandry applications for the territory of the People's Republic of Bangladesh.

QuicksolTM is the Company's patented solubilization technology, which has been developed to provide solubilized drug delivery options across the macrocyclic lactone class of anti-parasitic drugs and is the principal technology applied to SoluvecTM. To safeguard its intellectual property and the Company's licensing royalty model, MVMD has filed for its principal QuicksolTM patent protection. These filings target key markets that the Company has deemed strategically important at this time where it is anticipated its SoluvecTM products will be sold in the future.

In April 2023, MVMD had filed for SoluvecTM protection in 12 additional markets outside of the United States, including Canada, China, India, Mexico, Sri Lanka, Thailand, Philippines, Malaysia, Brazil, Peru, Argentina, and Chile.